Friday 3 August 2018

This just in:

medpagetoday.com

ASCO Reading Room | Addition of a Personalized Vaccine to Standard Therapy in Glioblastoma

 

5 comments:

  1. I got really discouraged after reading this article :| weren't last results from Toca511 and DCVax kinda optimistic? And anyone knows if there are any preliminary results from the trial that combined vaccines with checkpoint inhibitors?

    ReplyDelete
  2. What did you find discouraging about the article? The final comments by Platten?
    This article was about the phase 3 DCVax trial, see here for previous discussion:
    https://btcocktails.blogspot.com/2018/05/dcvax-update.html

    The trial hasn't been unblinded yet, so all comments are about the entire trial population (those who got vaccine upfront as well as those who got placebo upfront with the option of vaccine at recurrence). The primary endpoint of the trial was progression-free survival, which hasn't been reported yet at all, because of the trial not being unblinded yet. It's too early to give a full evaluation of the trial. The thing to look for in these trial is not necessarily the median survival, but the tail of long term survivors in the 5-7 year range. Preliminary result are positive in this regard (as they were in the Toca trials, which weren't randomized).

    ReplyDelete
    Replies
    1. I haven't seen any results, not even preliminary results or abstracts, on the combination of vaccines or viral therapies with checkpoint inhibitors for glioma. The furthest along is DNX-2401 + pembrolizumab, which opened mid 2016.
      https://clinicaltrials.gov/ct2/show/NCT02798406

      Pembrolizumab with or without HSPPC-96 vaccine opened early 2017
      https://clinicaltrials.gov/ct2/show/NCT03018288

      I've seen no results yet for either of these trials

      Delete
    2. I agree with you, even looking at the median survival it's better than contemporary studies. I don't know why people are so negative on the data.

      Delete
  3. This is a pretty nice DCVax write-up (though from a conflicted source due to author's association with a hedge fund which is invested in the biotech company owning DCVax, so also to be read as such):

    http://static1.1.sqspcdn.com/static/f/428566/28026405/1542231723430/NWBO+-+White+Paper+Rago_48081593.pdf?token=rR5pmAu4TehqLK0U%2BLSPRCSSEGw%3D

    By the way, the DCVax trial seems to be about to get un-blinded very soon now, hopefully with strong results.

    ReplyDelete